P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)

Bibliographic Details
Main Authors:	Marina Konopleva, Courtney D. Dinardo, Yan Sun, Sanam Loghavi, Paul Jung, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000968992.16092.8c

Similar Items

Venetoclax for AML: changing the treatment paradigm
by: Daniel A. Pollyea, et al.
Published: (2019-12-01)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS
by: S. Garciaz, et al.
Published: (2022-06-01)

P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
by: J.-Z. Hou, et al.
Published: (2022-06-01)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
by: N. Daver, et al.
Published: (2022-06-01)

P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)
by: E. Stein, et al.
Published: (2022-06-01)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
by: Hua Jin, et al.
Published: (2023-04-01)

A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML
by: Daver, NG, et al.
Published: (2022)

P1350: M2-LIKE MONOCYTE-DERIVED MACROPHAGES PROTECT AML CELL LINES AND PRIMARY AML CELLS AGAINST THERAPY-INDUCED APOPTOSIS
by: Katerina Miari, et al.
Published: (2023-08-01)

Monoclonal antibodies differentiating between monocytic and nonmonocytic variants of AML.
by: Linch, D, et al.
Published: (1984)

P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE
by: David Sharon, et al.
Published: (2023-08-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
by: T. Ueda, et al.
Published: (2024-01-01)

P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML
by: N. G. Daver, et al.
Published: (2022-06-01)

Mechanisms of response and resistance to AML therapies
by: Stoilova, B, et al.
Published: (2020)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

P412: LOW EXPOSURE, EXTENDED DOSING MIMICKING CLINICAL EXPOSURES OF ORAL AZACITIDINE SYNERGIZES WITH VENETOCLAX IN PRECLINICAL AML MODELS
by: D. Jeyaraju, et al.
Published: (2022-06-01)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
by: Danielle Hammond, et al.
Published: (2023-09-01)

miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
by: Yilan Xu, et al.
Published: (2025-02-01)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
by: Nicholas J. Short, et al.
Published: (2023-07-01)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
by: Wenjian Wei, et al.
Published: (2023-08-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
by: A. Shastri, et al.
Published: (2024-01-01)

FEATURES OF A DIFFERENTIAL DIAGNOSIS OF PEDIATRIC ACUTE MONOCYTIC LEUKEMIA (AML-M5a) ON THE EXAMPLE OF A CLINICAL CASE
by: O. I. Kit, et al.
Published: (2020-03-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
by: Sandra Huber, et al.
Published: (2023-08-01)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
by: L. Minarik, et al.
Published: (2022-06-01)

MicroRNA-mRNA Pairs Associated with Outcome in AML: From in vitro Cell-based Studies to AML Patients
by: Neha S Bhise, et al.
Published: (2016-01-01)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
by: Juan Miguel Bergua Burgues, et al.
Published: (2023-08-01)

MOZ Forms an Autoregulatory Feedback Loop with miR-223 in AML and Monocyte/Macrophage Development
by: Ming Jiang, et al.
Published: (2019-01-01)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
by: Warren Fiskus, et al.
Published: (2023-04-01)

Acute erythroid leukemia (AML-M6) - Is it rare?
by: Rashmi Patnayak, et al.
Published: (2009-03-01)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
by: Hong Pan, et al.
Published: (2023-08-01)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
by: António Almeida, et al.
Published: (2017-01-01)

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML
by: Naidu M. Vegi, et al.
Published: (2016-07-01)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
by: Jorge Cortes, et al.
Published: (2023-08-01)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
by: Mikhail S Chesnokov, et al.
Published: (2021-07-01)

CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML
by: Esmaeil Shahabi Satlsar, et al.
Published: (2020-11-01)

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
by: Ioannis Mantzaris, et al.
Published: (2023-08-01)

AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.
by: Alessandro Gardini, et al.
Published: (2008-11-01)

Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype.
by: Dawn Sijin Nin, et al.
Published: (2012-01-01)